Bacterial Conjunctivitis-Pipeline Review, H1 2017

Bacterial Conjunctivitis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9211IDB
  • |
  • Pages: 35
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Bacterial Conjunctivitis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis-Pipeline Review, H1 2017, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape.

Bacterial conjunctivitis is an inflammation of the conjunctiva caused by pathogenic bacteria. Bacterial conjunctivitis is usually caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus sp, or, less commonly, Chlamydia trachomatis. Symptoms include redness in the white of the eye or inner eyelid, itchy eyes, blurred vision, increased sensitivity to light and burning eyes. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Conjunctivitis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Unknown stages are 3, 1, 1 and 1 respectively.

Bacterial Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bacterial Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bacterial Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bacterial Conjunctivitis (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bacterial Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bacterial Conjunctivitis-Overview

Bacterial Conjunctivitis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Bacterial Conjunctivitis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bacterial Conjunctivitis-Companies Involved in Therapeutics Development

Allergan Plc

InSite Vision Inc

Laboratorios Sophia SA de CV

Shire Plc

Bacterial Conjunctivitis-Drug Profiles

acorafloxacin hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

azithromycin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISV-405-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazufloxacin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-640-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vancomycin hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bacterial Conjunctivitis-Dormant Projects

Bacterial Conjunctivitis-Product Development Milestones

Featured News & Press Releases

Jun 17, 2015: Manhattan U.S. Attorney Settles Civil Fraud Claims Against Inspire Pharmaceuticals For Its Misleading Marketing Designed To Cause Prescriptions Of Azasite For Non-Fda Approved Uses

Mar 17, 2015: InSite Vision Announces Settlement of Patent Infringement Lawsuit Against Mylan Pharmaceutical

Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US

Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops

Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops

Jun 17, 2013: InSite Vision Announces Joint Patent Infringement Lawsuit With Merck Against Mylan Pharma

Mar 26, 2013: InSite Vision Wins Appeal Of Patent Interference Litigation Against University Of California, San Francisco

Jan 05, 2012: University Of California, San Francisco Files Appeal Of USPTO Judgment In Favor Of InSite Vision

Nov 28, 2011: InSite Vision Wins Patent Interference Litigation Against University Of California, San Francisco

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Bacterial Conjunctivitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Bacterial Conjunctivitis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Bacterial Conjunctivitis-Pipeline by Allergan Plc, H1 2017

Bacterial Conjunctivitis-Pipeline by InSite Vision Inc, H1 2017

Bacterial Conjunctivitis-Pipeline by Laboratorios Sophia SA de CV, H1 2017

Bacterial Conjunctivitis-Pipeline by Shire Plc, H1 2017

Bacterial Conjunctivitis-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Allergan Plc, InSite Vision Inc, Laboratorios Sophia SA de CV, Shire Plc

select a license

Single User License
USD 2000 INR 129560
Site License
USD 4000 INR 259120
Corporate User License
USD 6000 INR 388680

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com